cashmagnet
2 minutes ago
Well put...The possibilities for Bioxytran are indeed staggering, potentially. The issue with startups--as ever--is funding, exposure, and timing. It looks like we're off to a good start with financing. As long as the company is well run and well connected at some point it seems like it's only a mat